Search - tctmd.com

Displaying 1 - 11 of 11

Sort: Relevancy | Date

News Conference News ACC 2024

Triglyceride-Lowering Therapies Provide Favorable Outcomes in Early Testing

Michael O'Riordan

April 12, 2024

Presentation ACC 2024

Effect of Alcohol-mediated Renal Denervation on Blood Pressure in the Presence of Antihypertensive Drugs: 3-month Primary Results From the Target BP I Randomized Trial

Presenter: David E. Kandzari

April 08, 2024

News Conference News ACC 2023

HALO: Baxdrostat No Better Than Placebo in Uncontrolled Hypertension

Todd Neale

March 08, 2023

News Conference News ACC 2023

No Downside to Immediate Complete Revascularization in ACS: BIOVASC

Michael O'Riordan

March 06, 2023

News Conference News ACC 2022

No Difference in 1-Year QoL Between FFR-Guided PCI and CABG: FAME-3

Michael O'Riordan

April 13, 2022

News Conference News ACC 2022

ADAPT-TAVR: Edoxaban No Better Than DAPT After TAVI

Todd Neale

April 05, 2022

Presentation ACC 2022

Long Term Efficacy and Safety of Renal Denervation on Blood Pressure in Patients on Antihypertension Medications: 3-Year Outcomes from the SPYRAL HTN-ON MED Trial

Presenter: Felix Mahfoud

April 04, 2022

News Conference News ACC 2022

POISE-3: Tranexamic Acid Stems Bleeding During Noncardiac Surgery

Todd Neale

April 02, 2022

News Conference News ACC 2020

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

Michael O'Riordan

April 02, 2020

News Conference News ACC 2018

High CRP Linked to Bigger Absolute Drops in CV Events for Patients Taking Evolocumab

Michael O'Riordan

March 20, 2018

News Conference News ACC 2018

Gout Drug Febuxostat Linked to More CV Deaths Without Uptick in CV Events: CARES Trial

Caitlin E. Cox

March 14, 2018

Advertisement

Triglyceride-Lowering Therapies Provide Favorable Outcomes in Early Testing

Effect of Alcohol-mediated Renal Denervation on Blood Pressure in the Presence of Antihypertensive Drugs: 3-month Primary Results From the Target BP I Randomized Trial

HALO: Baxdrostat No Better Than Placebo in Uncontrolled Hypertension

No Downside to Immediate Complete Revascularization in ACS: BIOVASC

No Difference in 1-Year QoL Between FFR-Guided PCI and CABG: FAME-3

ADAPT-TAVR: Edoxaban No Better Than DAPT After TAVI

Long Term Efficacy and Safety of Renal Denervation on Blood Pressure in Patients on Antihypertension Medications: 3-Year Outcomes from the SPYRAL HTN-ON MED Trial

POISE-3: Tranexamic Acid Stems Bleeding During Noncardiac Surgery

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

High CRP Linked to Bigger Absolute Drops in CV Events for Patients Taking Evolocumab

Gout Drug Febuxostat Linked to More CV Deaths Without Uptick in CV Events: CARES Trial

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content